BioNTech could step up capacity to 3bn Covid-19 vaccine doses in 2022

German pharmaceuticals firm BioNTech has said it can step up production of its coronavirus vaccine to keep up with demand.

The German company could produce up to 3 billion Covid-19 vaccine doses with its US partner Pfizer if needed in 2022, BioNTech’s chief executive officer Ugur Sahin told the Bloomberg financial wire on Tuesday.

But this also depended on demand and whether booster shots are needed, he added. 3 billion doses would be a 50 per cent increase on the 2 billion planned for 2021.